US Patent

US8371292 — Use of ciclesonide for the treatment of respiratory diseases

Method of Use · Assigned to Nycomed GmbH · Expires 2028-02-01 · 2y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using ciclesonide for the treatment of respiratory diseases in asthmatic children.

USPTO Abstract

The invention relates to new method of treatment of respiratory diseases, in particular the treatment of asthmatic children.

Drugs covered by this patent

Omnaris (CICLESONIDE) · Covis

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1357`	—	Omnaris
`U-1355`	—	Omnaris
`U-1356`	—	Omnaris
`U-1355`	—	Omnaris

Patent Metadata

Patent number: US8371292
Jurisdiction: US
Classification: Method of Use
Expires: 2028-02-01
Drug substance claim: No
Drug product claim: No
Assignee: Nycomed GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.